Artelo Biosciences
ARTL
5 hedge funds and large institutions have $35.7K invested in Artelo Biosciences in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
0% more ownership
Funds ownership: 0.04% → 0.04% (+0%)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
4% less capital invested
Capital invested by funds: $37.2K → $35.7K (-$1.51K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.35K |
| 2 |
Citigroup
New York
|
+$75 |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$25 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$185 |
| 2 |
Wells Fargo
San Francisco,
California
|
-$37 |
| 3 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$1 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Geode Capital Management
Boston,
Massachusetts
| $27.7K | – | – | – |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $7.8K | +$1.35K | +54 | +20% |
|
|
3
Citigroup
New York
| $64 | +$75 | +3 | New |
|
|
4
Bank of America
Charlotte,
North Carolina
| $35 | +$25 | +1 | New |
|
5
Morgan Stanley
New York
| $27 | – | – | – |
|
|
RIL
6
Rothschild Investment LLC
Chicago,
Illinois
| $11 | – | – | – |
|
|
7
UBS Group
Zurich,
Switzerland
| – | -$185 | -7 | Closed |
|
|
8
Wells Fargo
San Francisco,
California
| – | -$37 | -1 | Closed |
|
|
NA
9
NewEdge Advisors
New Orleans,
Louisiana
| – | -$1 | – | – |
|
ARTL Hedge Fund Activity: Q2 2024 in Review
5 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q2 2024, worth a combined $35.7K — down 4.1% from $37.2K a quarter earlier.
Fund positioning in ARTL was balanced in Q2 2024: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Tower Research Capital (TRC), adding an estimated $1.35K. The largest seller was UBS Group, exiting entirely with an estimated $185 sold.
- 5 institutional investors held Artelo Biosciences (ARTL) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $35.7K of Artelo Biosciences stock for Q2 2024, down 4.1% quarter-over-quarter.
- 2 funds opened new Artelo Biosciences positions in Q2 2024 and 2 closed out, a net change of 0 holders.
- The largest Artelo Biosciences buyer in Q2 2024 was Tower Research Capital (TRC), an estimated $1.35K added.
- The largest Artelo Biosciences seller in Q2 2024 was UBS Group, an estimated $185 sold.
Based on aggregated 13F filings for Q2 2024.